Resurgent Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$863K Buy
6,755
+4,853
+255% +$606K 0.31% 77
2025
Q4
$232K Sell
1,902
-3,905
-67% -$448K 0.12% 195
2025
Q3
$582K Sell
5,807
-1,103
-16% -$99.3K 0.29% 105
2025
Q2
$573K Buy
6,910
+2,163
+46% +$173K 0.31% 94
2025
Q1
$385K Buy
4,747
+2,152
+83% +$192K 0.23% 121
2024
Q4
$234K Sell
2,595
-2,322
-47% -$225K 0.14% 160
2024
Q3
$486K Sell
4,917
-343
-7% -$33.7K 0.28% 105
2024
Q2
$488K Buy
5,260
+628
+14% +$56.3K 0.3% 103
2024
Q1
$439K Buy
4,632
+1,483
+47% +$138K 0.23% 116
2023
Q4
$281K Sell
3,149
-3,037
-49% -$226K 0.17% 136
2023
Q3
$452K Sell
6,186
-415
-6% -$33.1K 0.31% 86
2023
Q2
$549K Sell
6,601
-157
-2% -$13.1K 0.36% 73
2023
Q1
$515K Buy
6,758
+1,400
+26% +$116K 0.34% 74
2022
Q4
$445K Sell
5,358
-146
-3% -$11.8K 0.23% 100
2022
Q3
$436K Buy
5,504
+2,274
+70% +$192K 0.29% 98
2022
Q2
$240K Buy
+3,230
New +$242K 0.15% 156

Other funds holding XBI

Resurgent Financial Advisors's XBI Position: Q1 2026 in Review

Resurgent Financial Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 255% in Q1 2026, buying an estimated $606K and bringing the position to 6,755 shares worth $863K. The position accounts for 0.31% of the portfolio, ranked #77.

Resurgent Financial Advisors first reported a position in XBI in Q2 2022 and has held it in 16 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Resurgent Financial Advisors held 6,755 shares of State Street SPDR S&P Biotech ETF worth $863K as of Q1 2026.
  • Resurgent Financial Advisors bought 4,853 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $606K.
  • State Street SPDR S&P Biotech ETF made up 0.31% of Resurgent Financial Advisors's portfolio in Q1 2026, its #77 holding.
  • Resurgent Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 16 quarters since.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Resurgent Financial Advisors's 13F filing for Q1 2026, filed 13 May 2026.